4.3 Article

Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition

Journal

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES
Volume 22, Issue 4, Pages 249-273

Publisher

WILEY
DOI: 10.1002/jhbp.233

Keywords

Ampullary carcinoma; Bile duct carcinoma; Biliary tract cancer; Gallbladder carcinoma

Funding

  1. Isayama H, Boston Scientific Japan, Tokyo, Japan
  2. Taiho Pharma, Tokyo, Japan
  3. Yakult Pharmaceutical Industry Co., Ltd., Tokyo, Japan
  4. Piolax Inc., Yokohama, Japan
  5. Unno M, Takeda Pharmaceutical Co., Ltd., Osaka, Japan
  6. Chugai pharmaceutical Co., Ltd., Tokyo, Japan
  7. Janssen Pharmaceutical K., K., Tokyo, Japan
  8. Ousaka T, Taiho Pharma, Tokyo, Japan
  9. Onco Therapy Science, Inc., Kawasaki, Japan
  10. Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan
  11. Bayer Yakuhin, Osaka, Japan
  12. Eisai Co., Ltd., Tokyo, Japan
  13. Bristol-Myers Squibb, Tokyo, Japan
  14. Eli Lily Japan
  15. Kobe, Japan
  16. Novartis Pharma, Tokyo, Japan
  17. Takeda Pharmaceutical Co., Ltd., Osaka, Japan
  18. Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan
  19. Boehringer Inglheim Japan, Inc., Tokyo, Japan
  20. Kowa Pharmaceutical Co., Ltd., Tokyo, Japan
  21. Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan
  22. Merck Serono Japan, Tokyo, Japan
  23. Ono pharmaceutical Co., Ltd., Osaka, Japan
  24. AstraZeneca K. K., Osaka, Japan
  25. Furuse J, Taiho Pharma, Tokyo, Japan
  26. Pfizer Japan Inc., Tokyo, Japan
  27. Glaxo SmithKline K. K., Tokyo, Japan
  28. Zeria Pharmaceutical Co., Ltd., Tokyo, Japan
  29. Miyazaki M, Eli Lily Japan
  30. Sanofi K. K., Tokyo, Japan
  31. Murakami K, FUJIFILM RI Pharma Co., Ltd., Tokyo, Japan

Ask authors/readers for more resources

Background The Japanese Society of Hepato-Biliary-Pancreatic Surgery launched the clinical practice guidelines for the management of biliary tract and ampullary carcinomas in 2008. Novel treatment modalities and handling of clinical issues have been proposed after the publication. New approaches for editing clinical guidelines, such as the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system, also have been introduced for better and clearer grading of recommendations. Methods Clinical questions (CQs) were proposed in seven topics. Recommendation, grade of recommendation and statement for each CQ were discussed and finalized by evidence-based approach. Recommendation was graded to grade 1 (strong) and 2 (weak) according to the concept of GRADE system. Results The 29 CQs covered seven topics: (1) prophylactic treatment, (2) diagnosis, (3) biliary drainage, (4) surgical treatment, (5) chemotherapy, (6) radiation therapy, and (7) pathology. In 27 CQs, 19 recommendations were rated strong and 11 recommendations weak. Each CQ included the statement of how the recommendation was graded. Conclusions This guideline provides recommendation for important clinical aspects based on evidence. Future collaboration with cancer registry will be a key for assessment of the guidelines and establishment of new evidence. Free full-text articles and amobile application of this guideline are available via http://www.jshbps.jp/en/guideline/biliary-tract2.html.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available